Late gadolinium enhancement (LGE) on cardiac magnetic resonance imaging (CMR) is believed to represent dense replacement fibrosis. It is seen in ≈60% of adult patients with hypertrophic cardiomyopathy (HCM). However, the prevalence of LGE in children and adolescents with HCM is not well established. In addition, longitudinal studies describing the development and evolution of LGE in pediatric HCM are lacking. This study assesses the prevalence, progression, and clinical correlations of LGE in children and adolescents with, or genetically predisposed to, HCM.
H
ypertrophic cardiomyopathy (HCM) is morphologically characterized by primary hypertrophy of the myocardium, myocyte disarray, and myocardial fibrosis. The presentation of HCM is highly heterogeneous and encompasses the entire spectrum from asymptomatic incidental diagnosis to sudden cardiac death to advanced heart failure. 1, 2 Myocardial fibrosis in HCM is seen both as diffuse interstitial fibrosis, and dense focal replacement fibrosis, as well, and thought to be an important substrate for both heart failure and arrhythmias. 3 The presence and extent of focal replacement fibrosis can be assessed noninvasively by late gadolinium enhancement (LGE) on cardiac magnetic resonance imaging (CMR). 4 In adult patients with overt HCM, LGE is identified in ≈60% of the population, increases over time, and is associated with adverse outcomes. [4] [5] [6] [7] Sarcomere mutation carriers with normal left ventricular wall thickness have evidence of altered serum biomarkers of collagen metabolism and increased extracellular volume assessed with CMR, suggesting a profibrotic state even before the development of left ventricular hypertrophy (LVH). 8, 9 However, LGE is hardly ever observed in mutation carriers without LVH. 8, 10, 11 Although multiple studies have evaluated fibrosis by LGE in adults with HCM, our knowledge regarding its presence in children with HCM is limited. Moreover, longitudinal studies describing the development of LGE over time in children and adolescents are lacking. [12] [13] [14] [15] [16] The purpose of this study was to assess the presence and extent of focal replacement fibrosis by LGE in a large cohort of children and adolescents with, or predisposed to, HCM, and to investigate the progression of LGE over time.
METHODS Study Population and Design
This is an observational, retrospective study. Data were obtained from children and adolescents (≤21 years) who had at least 1 CMR either as part of participation in the multicenter HCMNet study (Hypertrophic Cardiomyopathy Network) (n=39; HCMNet investigators and sites listed in Table I in the online-only Data Supplement) conducted from 2010 to 2012, or had CMR imaging performed for routine clinical care (n=156) at the 9 participating institutions between 2008 and 2015 17 ( Figure I in the online-only Data Supplement). Participants were defined as either overt HCM: clinical diagnosis of HCM based on LVH on echocardiography or CMR (defined as maximal left ventricle [LV] wall thickness of at least 15 mm for patients 18-21 years; for patients <18 years, maximal LV wall thickness either ≥15 mm or z score >3 SDs above the predicted mean with a sarcomere mutation and a family history of HCM and either ≥15 mm, or z score >5 without sarcomere mutations or family history of HCM) 17, 18 or mutation carriers without LVH: individuals carrying a pathogenic or likely pathogenic sarcomere mutation but normal LV wall thicknesses (<15 mm and z score <3). One patient was originally assessed at 9 years of age after his father was found to have an enlarged heart at autopsy, but without formal postmortem criteria for HCM and diagnosed with HCM on the basis of a maximal wall thickness of 12 mm on CMR (z score 3.93) with a septal-to-free wall ratio of 1.8, systolic anterior motion of the mitral valve, and left ventricular ejection fraction (LVEF) 71%. At follow-up CMR 2 years later, maximal wall thickness was 14 mm (z score 5.47). Patients with coexisting syndromic or congenital heart disease, inborn errors of metabolism, or storage disorders and patients believed to have physiological LVH attributable to athletic participation, hypertension, or other forms of hemodynamic overload were excluded. Patient charts were reviewed for demographic, genetic, and clinical data. Genetic variants were classified as pathogenic, likely pathogenic, variant of uncertain significance, likely benign, or benign by the genetic testing laboratory, according to standard criteria including review of databases and literature, frequency in the general population (accounting for ethnicity), and segregation within affected families. 19, 20 The institutional review boards at all participating sites approved the study protocol. For subjects who received imaging as part of research participation, adults provided written informed consent, and parental consent or youth assent was obtained for younger
Clinical Perspective
What Is New?
• In this study, we report cardiac magnetic resonance imaging data from 195 children and adolescents with hypertrophic cardiomyopathy.
• Late gadolinium enhancement on cardiac magnetic resonance imaging, indicating myocardial replacement fibrosis, was present in 46% of patients with overt hypertrophy, in comparison with ≈60% typically reported in adult hypertrophic cardiomyopathy.
• Late gadolinium enhancement was not seen in mutation carriers without left ventricular hypertrophy.
• In patients who underwent serial imaging, increases in late gadolinium enhancement, left ventricular mass, and left atrial size were detected over 2.5 years.
What Are the Clinical Implications?
• Our findings in children provide additional insights into the biology and natural history of hypertrophic cardiomyopathy and confirm that fibrosis is a significant part of the disease process in both children and adults.
• Our results indicate that disease progression occurs over time and highlight the importance of longitudinal follow-up throughout life.
• Additional prospective, longitudinal cohort studies are needed to better understand the clinical implications of late gadolinium enhancement in pediatric hypertrophic cardiomyopathy.
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participants. The data, analytic methods, and study materials will not be made available to other researchers for purposes of reproducing the results or replicating the procedure.
Cardiac Magnetic Resonance Imaging
CMR was performed using 1.5 or 3 Tesla scanners with ECG gating and breath-hold technique. For quantification of cardiac volumes and mass, balanced steady-state free precession cine images were obtained as a short-axis stack covering the LV. For assessment of LGE, T1-weighted, gradient echo images were obtained as a short-axis stack covering the LV, ≈10 minutes after the administration of an intravenous bolus of gadolinium contrast (0.1-0.2 mmol/kg). Inversion time was continuously determined to null the signal from the normal myocardium. For patients who underwent serial CMR scans, all scans were performed at the same magnetic field strength. Images were analyzed by 1 reader (A.A.R.), blinded to clinical data, using CVI42 software (Circle Cardiovascular Imaging Inc). Epi-and endocardial borders of the LV were traced from the contiguous short-axis stack in end-diastole. LV mass in grams was calculated by the software as the volume between the 2 borders multiplied by the myocardial density (1.05 g/cm 3 ), excluding papillary muscles and presented as indexed to body surface area (BSA) and as SD above the predicted mean in a healthy pediatric population. 21 Maximal LV wall thickness was defined as the greatest thickness measured perpendicular to the myocardial border in the short-axis images in end-diastole. Maximal wall thickness was measured manually and confirmed by the software's automatic function for wall thickness. LGE images were first reviewed for visible LGE (areas with relatively increased signal intensity following administration of gadolinium contrast), and if positive, quantified. Quantification was performed both as a signal intensity threshold of >6 SD above remote myocardium and using the full width/half maximum (FWHM) method. 22 If the stack did not cover the whole LV or if the myocardium was not nulled appropriately in all slices, LGE was not quantified but only assessed as present or not (n=8). Manual correction was performed for obvious threshold errors. The extent of LGE is presented in grams and as the percentage of total LV mass. For serial assessment, the reference area was placed in the same part of the myocardium for both scans. The left atrial area was traced in the 2-and 4-chamber views excluding the left atrial appendage, and the volume was calculated by using the area-length method.
Statistical Analysis
Statistical analysis was performed using SAS version 9.4. Maximal LV wall thickness is presented as a z score; the number of SDs from the normal population mean. 18, 23 Normally distributed continuous variables are presented as mean±SD and nonnormally distributed data as median and interquartile range (IQR). Normally distributed, within-individual changes over time were evaluated using the paired t test and nonnormally distributed continuous variables with the signedrank test. Between-group differences were analyzed with the unpaired t test, Wilcoxon 2-sample test, or χ 2 test, depending on type of variable and distribution. Linear and logistic regression analyses were applied to explore the relation between covariates. Variables were assessed with univariable analysis, and those with a P value of <0.10 were fitted into a multivariable regression model. A 2-sided P value of <0.05 was considered significant.
RESULTS

Clinical and Genetic Characteristics of the Patient Population
A total of 195 children and adolescents (mean age at study entry, 14.3±4.5 years, 68% males) were included in the study, 155 (79%) with overt HCM and 40 mutation carriers without LVH. Demographic and genetic characteristics are summarized in Table 1 . The mean age of diagnosis in patients with overt HCM was 11.4±5.4 years (age at diagnosis available in 125 [81%] patients). Mean time from diagnosis to CMR was 3.3±3.9 years (range, 0-18 years). In total, 123 patients (63%) had undergone genetic testing, which included both initial diagnostic testing as proband, and predictive testing to determine if a known family variant was present. Pathogenic or likely pathogenic mutations had been identified in 61 (73%) of the 83 patients with overt HCM who underwent genetic testing.
CMR Findings
Maximal LV wall thickness on CMR was 22.4±8.4 mm in patients with overt HCM, corresponding to a median z score of +15.7 (IQR, 7.4-22.4). LVEF was 76% (IQR, 70-81%). Three patients (1.5%), with ages 10 days, 8 years, and 21 years, had reduced LVEF (<50%), of 15%, 47%, and 47%, respectively. Gadolinium was administered in 152 (98%) patients with overt HCM and LGE was detected in 70 (46%; 95% confidence interval [CI], 38-54%), including 1 of the 3 patients with a reduced LVEF (8-year-old boy, LVEF 47%). Patient characteristics and CMR findings for LGE-positive and LGE-negative patients with overt HCM are shown in Table 2 .
The most common location for LGE was the septum or the adjacent right ventricular insertion points. LGE was localized in the segments with most hypertrophy in the majority of patients (83%). Only 2 patients had LGE in segments without hypertrophy (anterior hypertrophy with LGE in the inferior right ventricular insertion point and septal hypertrophy with LGE in the posterior wall). In patients with LGE, the median extent was 3.3% (IQR, 0.8-7.1%) of LV mass when quantified as >6 SDs above the remote area, and 8.5% (IQR, 2.6-15.0%) using the FWHM method. Results for regression models are presented using the signal intensity >6 SDs throughout the article, but similar to findings using the FWHM method (Table II in the online-only Data Supplement).
Patients with LGE had more pronounced LVH than patients without LGE, exhibiting both 40% greater LV ORIGINAL RESEARCH ARTICLE mass and 200% greater z scores for maximal wall thickness ( Table 2 ). The extent of LGE was correlated with maximal wall thickness (r=0.42, P<0.0001). Maximal LV wall thickness was the only feature that was independently associated with the presence and extent of LGE (Tables 3 and 4 Genotyped patients with overt HCM with pathogenic or likely pathogenic sarcomere variants (n=61) were compared with those without identified sarcomere mutations (n=22). There were no significant differences 
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with regard to LV mass, maximal wall thickness, or the presence or extent of LGE in sarcomere mutation carriers in comparison with sarcomere-negative HCM. Furthermore, there were no significant differences for the same parameters between patients carrying variants in MYH7 (n=25) and MYBPC3 (n=28) (data not shown). CMR findings for the 40 mutation carriers without LVH are shown in Table 1 . Gadolinium was administered in 35 (88%) patients. LGE was not detected in any mutation carrier without LVH.
Findings in Patients Who Underwent Serial CMR
Thirty-one patients had >1 CMR with gadolinium performed over a median interval of 2.4 years (IQR, 1.5-3.2 years), including 9 patients with 3 CMRs and 2 patients with 4 CMRs.
Repeat imaging was obtained either in the course of clinical care (n=23) or in accordance with research protocols (n=8). Patients were on average 14.0±3.8 years at baseline and 16.5±4.4 at most recent CMR. LGE was detected in 13 (42%) of these patients at baseline. At the most recent study an additional 3 patients developed LGE, and thus, in total, 16 (52%) patients had LGE by the final CMR. Changes from baseline to the most recent CMR are shown in Table 5 . There was a statistically significant increase in the extent of LGE, both expressed as an absolute amount (from 1. Age, sex, presence of a pathogenic variant, LV mass at baseline, change in LV mass, maximal wall thickness, LVEF and LGE at baseline were not predictors of an increase in LGE when modeling change in LGE was the dependent variable (data not shown). In addition to LGE, LV mass and left atrial volume, indexed to BSA, and z score for LV mass, as well, increased significantly from first to most recent CMR. Four (13%) patients who underwent >1 CMR were mutation carriers without LVH at the time of the first CMR. Three of these patients fulfilled criteria for overt HCM at follow-up (maximal LV wall thickness >15 mm or z score >3), but only 1 had developed LGE.
Clinical Follow-Up and Adverse Events
Clinical events were ascertained in the full cohort 3.4 years (IQR, 1.5-5.2 years) after initial CMR, although 10 patients (5%) were lost to follow-up. Events were only identified in patients with overt HCM at baseline. In total, 28 (18%) patients with overt HCM experienced at least 1 of the following adverse events: all-cause death, aborted sudden cardiac death, appropriate implantable cardioverter-defibrillator therapy, cardiac transplantation, and documented atrial fibrillation. Four patients died at 2.5 months and 3, 6, and 22 years of age. All were diagnosed with HCM in infancy, and 1 had LGE on CMR (see the online-only Data Supplement for detailed description). After initial CMR, an implantable cardioverter-defibrillator was implanted in 49 (25%) patients at a mean age of 16.5±3.4 years. Ventricular tachycardia or ventricular fibrillation was documented in a total of 21 (13%) patients. Six of those patients had received an implantable cardioverter-defibrillator and had appropriate therapy for the arrhythmia. Two (1%) patients underwent cardiac 
DISCUSSION
In this study, we analyzed CMR images from nearly 200 children and adolescents who had HCM or were sarcomere mutation carriers without LVH. The major findings are the following: (1) Almost half (46%) of the children and adolescents with overt HCM had LGE on CMR; (2) maximal LV wall thickness was the only independent predictor of the presence and extent of LGE; (3) no sarcomere mutation carriers without LVH displayed LGE; and (4) LGE is progressive over time in children with HCM.
The prevalence and extent of LGE in adult patients with HCM have been assessed in several studies and consistently shown to be present in approximately two thirds of the population. 6, [24] [25] [26] [27] [28] [29] Much less is known about LGE in pediatric HCM. Previous smaller studies (median sample size, 31.5; range, 28-71 patients) have reported highly variable prevalence estimates, ranging from 18% to 73% of patients. [12] [13] [14] [15] [16] 30 Because our study encompasses a cohort nearly 3-fold larger, it may more accurately estimate prevalence and indicates that 46% of pediatric patients with HCM have LGE. Comparing the extent, as opposed to the presence, of LGE with other pediatric or adult studies is even more complex, in particular, because there is no consensus for how to quantify LGE in HCM. 24, 25, 27, 29 In adults, the average extent has been reported as being between 4% and 16% of LV mass, bearing in mind that differ- Variables with a P value <0.10 in the univariable analysis were fitted into a multivariable linear regression model. Variables were not found to be collinear (maximum variance inflation was 4.4, variance inflation for LVH variables <2). Results were similar if using a z score instead of absolute maximal wall thickness in mm (0.2% of LV mass/increase in z score, P=0.001). The finding of maximal wall thickness as the only significant predictor was consistent in a model where late gadolinium enhancement was logarithmically transformed (log10) before modeling to account for the skewedness of data (univariate 1.07, P=0.0019, multivariate 1.07, P=0.04). BSA indicates body surface area; CI, confidence interval; HCM, hypertrophic cardiomyopathy; LV, left ventricular; and LVH, left ventricular hypertrophy. Variables with a P value <0.10 in the univariable analysis were fitted into a multivariable logistic regression model. Variables were not found to be collinear (maximum variance inflation was 4.4, variance inflation for LVH variables <2). Results were similar if using a z score instead of absolute maximal wall thickness in mm (OR, 1.17; 95% CI, 1.10-1.27; P<0.0001). BSA indicates body surface area; CI, confidence interval; HCM, hypertrophic cardiomyopathy; LV, left ventricular; and OR, odds ratio.
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ent methods have been used, including different signal intensity thresholds above remote myocardium, the FWHM method, and manual tracing. 7, 24, 26, 27, 29 In our study, LGE occupied on average 3.3% of LV mass in patients with overt HCM when assessed as the area of signal enhancement >6 SDs above remote myocardium, and 8.5% with the FWHM method. Also, using a signal intensity >6 SD in similar but smaller pediatric populations, Windram et al 30 (n=38) found the extent of LGE to be 2 to 16% of the LV, and Chaowu et al 12 (n=71) found it to be 10±8%.
The molecular pathways leading from genotype to overt HCM phenotype with hypertrophy, disarray, and fibrosis remain incompletely characterized. Our findings in children provide additional insights into the biology of HCM, because fibrosis appears to be an important part of the disease process in both children and adults, although LGE does seem to be somewhat less prevalent and less extensive in pediatric patients than in adult patients with HCM. These findings support the hypothesis that a certain duration of disease may be necessary for the development of dense replacement fibrosis. [31] [32] [33] [34] However, LVH, expressed as maximal LV wall thickness, was the only predictor of the presence and extent of LGE in our study. Neither age at baseline nor time since diagnosis was predictive. Further multidisciplinary study is needed to determine how and why myocardial fibrosis develops in HCM.
Our data from the small subset of patients with serial CMR imaging add to the available body of evidence of HCM as a progressive disease. In adults, it has previously been shown that LGE increases over time. 6, 7, 35 In the pediatric population, prior echocardiographic studies have assessed the development of LVH and agerelated penetrance but, to the best of our knowledge, this is the first study assessing the progression of LGE in children and adolescents with, or at risk of, HCM. [31] [32] [33] We demonstrate a significant increase in LGE, and in age-and body size-adjusted LV mass and left atrial size over the course of 2.5 years. Studying adults with HCM, Todiere et al 7 found an average increase of LGE of 6 g over 2 years of follow-up, corresponding to an increase rate of 0.06 to 2.53 g/mo. Using the same method for quantification (>6 SD thresholding) in pediatric patients, we found a median increase of 7 g (range, -1 to 42 g) over a median of 2.4 years followup. In addition, 3 of the 18 patients who did not have LGE at baseline developed LGE during this interval. The clear evidence of progression of LVH and LGE in the smaller subset of subjects with longitudinal data contrasts with the lack of association between age and duration of disease when analyzing the cross-sectional data from the full cohort. Furthermore, it is unclear whether LGE develops continuously, or in a nonlinear manner. Indeed, it may be that the rate of accumulation of LGE is a more accurate predictor of clinical outcomes than either its presence or its extent. These findings emphasize that findings from cross-sectional studies may not accurately reflect the longitudinal behavior of a disease like HCM with a highly variable natural history. Additional prospective, longitudinal cohort data are needed to enable an adequate description of disease development.
We acknowledge that the limited number of patients studied introduces some degree of inaccuracy of prevalence estimates. We also acknowledge that selection bias is an important concern, both for baseline imaging studies and for followup imaging. As such, these results may not be fully representative of or generalizable to the pediatric HCM population. The routine clinical practice of all investigators in this study was to obtain a baseline CMR on all patients with overt HCM as long as there were no contraindications to imaging, and patients were old enough to cooperate without sedation (typically age 7-8 years). In patients at risk for HCM but without hypertrophy on echocardiography, CMR was obtained to clarify ambiguous cases, such as suspected apical hypertrophy, or if echocardiographic imaging was suboptimal. Among study investigators, routine practice also included repeat imaging every 1 to 3 years during longitudinal followup to assess for changes over time. Therefore, based on the larger number of patients and multicenter experience in this study, we feel that these results are reasonably reflective of the real-world experience of young HCM patients but recognize that selection and referral bias cannot be completely excluded.
A signal intensity of ≥6 SDs above remote myocardium has been shown to have the best accuracy 22 and enabled comparisons with the recent studies by Smith et al, 13 and Windrow et al. 30 We found similar results using both signal intensity >6 SDs and FWHM, which is reassuring. Given the diffuse and heterogeneous nature of fibrosis in HCM, T1 mapping, with estimation of extracellular volume, may be a more sensitive method to assess the total amount of fibrosis and to assess for changes over time. This is especially relevant for mutation carriers without LVH who do not have quantifiable LGE was detected in 13 (42%) patients at baseline. In the most recent study, another 3 patients had developed LGE, and, in total, 16 (52%) patients had LGE. The extent of LGE, assessed as 6 SD above remote myocardium, increased significantly from median 1.5 g (IQR, 0.0-3.5 g) to 7.5 g (IQR, 4.0-16.0 g; P=0.01) and when expressed as percentage of left ventricular mass, from 2.9% (IQR, 0.6-3.2%) to 4.3% (IQR, 2.9-6.8%; P=0.02). CMR indicates cardiac magnetic resonance imaging; and IQR, interquartile range.
A B Figure 2 . Progression of LGE in 2 boys with overt hypertrophic cardiomyopathy. A, A 14-year-old boy carrying a myosin-binding protein C mutation. Top, Contrast-enhanced, short-axis images at 3 different levels demonstrating discrete LGE in the anterior and posterior hingepoints (arrows) in CMR performed at 14 years of age. Bottom, Repeat CMRs 1 year later demonstrate an increase in the amount of LGE at the corresponding locations (arrows). Maximal wall thickness increased from 30 to 35 mm in the same interval. B, A 13-year-old boy carrying 3 variants of unknown significance. Top, Contrast-enhanced, short-axis images at 3 different levels demonstrating discrete LGE in the anterior and posterior hingepoints (arrows) in CMR performed at 13 years of age. Bottom, Repeat CMRs 2 years later demonstrate an increase in the amount of LGE at the corresponding locations (arrows). Maximal wall thickness increased from 43 to 46 mm in the same interval. CMR indicates cardiac magnetic resonance imaging; and LGE, late gadolinium enhancement.
